We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Molecular Test Detects Three Arboviruses in Plasma Samples

By LabMedica International staff writers
Posted on 04 Aug 2016
Currently, multiple arboviruses are circulating in Brazil: Zika, chikungunya and dengue and they have similar clinical pictures, which can lead to misdiagnosis based on clinical grounds alone.

Detection tests for viral ribonucleic acid (RNA) such as the quantitative reverse transcription polymerase chain reaction (RT-qPCR) can reliably and specifically distinguish the three viruses and the specific diagnosis can be important in anticipating, preventing, and managing complications.

Scientists at the Laboratório Sabin (Brasília, Brazil) and their colleagues collected 90 plasma samples from the routine arbovirus laboratory, 20 positive for Zika (RT-qPCR), six positive for chikungunya (RT-qPCR), 18 positive for dengue nonstructural protein 1 antigen test (NS-1) and 46 negative for all three viruses. More...
Nucleic acids were extracted from 1mL of sample by using an automated DNA extractor. An in-vitro transcribed random RNA sequence, which is not found in the nature, was spiked into plasmas during the nucleic acids extraction to function as a process control. Primers/probes for chikungunya were specifically designed for this study.

Zika, chikungunya and dengue viruses were assessed simultaneously by RT-qPCR, but in independent reaction wells. The control RNA was co-amplified in all instances. The viral loads of specific samples were quantified against a serial dilution of synthetic single-stranded DNA (ssDNA) and the limits of detection of each assay were determined by probit regression analysis. To investigate the precision of the assays, three samples at ~72, ~7.2 and ~0.72 copies/mL of each viruses were evaluated by using the Clinical and Laboratory Standards Institute (CLSI) EP12-A2 method during five days in quadruplicate by two operators.

The investigators reported that the limits of detection were 26 copies/mL for Zika, 23.5 copies/mL, for chikungunya and 25.6 copies/mL for dengue. The ~72, ~7.2 and ~0.72 copies/mL samples yielded 18/20 (90%), 2/20 (10%) and 1/20 (5%) positive results for Zika, 18/20 (90%), 4/20 (20%) and 0/20 (0%) positive results for chikungunya and 20/20 (100%), 16/20 (80%) and 0/20 (0%) positive results for dengue, respectively. The total, positive and negative agreements between compared methods were 95.5%, 90% and 97.5 for Zika, 100% for all methods for chikungunya and 95.6%, 100% and 94.5%, for dengue, respectively. No cross-reaction was observed.

The authors concluded that the RT-PCR method for simultaneous detection of Zika, chikungunya and dengue viruses is highly sensitive, all assays showed limit of detection below 50 copies/mL. Moreover, cut-off regions were characterized and acceptable precisions were observed for positive (~72 copies/mL and above) and negative (~0.72 copies/mL and below) results. Finally, the agreements with the comparative methods were very good, above 90% of concordance in all instances. The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.

Related Links:
Laboratório Sabin
American Association of Clinical Chemistry

New
Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.